Previous Close | 8.73 |
Open | 8.64 |
Bid | 6.45 x 1100 |
Ask | 9.00 x 1100 |
Day's Range | 8.34 - 8.66 |
52 Week Range | 6.00 - 14.40 |
Volume | |
Avg. Volume | 90,477 |
Market Cap | 254.758M |
Beta (5Y Monthly) | 1.59 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.75 |
Earnings Date | Nov 08, 2022 - Nov 14, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 20.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for ALPN
Alpine Immune Sciences, Inc. (ALPN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The big shareholder groups in Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) have power over the company. Generally...
SEATTLE, August 11, 2022--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2022.